Does Blue Cross Blue Shield of Michigan Cover Forteo?

How BCBSM Classifies Forteo on Its Formulary

Blue Cross Blue Shield of Michigan places Forteo (teriparatide) on the specialty tier of its prescription drug formulary for both commercial and Medicare Advantage plans. This classification means the drug carries higher cost-sharing than preferred generics or brand-name oral medications used for osteoporosis.

BCBSM maintains separate formularies for its PPO, HMO (Blue Care Network), and Medicare Advantage products. Across all three, Forteo consistently appears as a covered but non-preferred specialty biologic. The Endocrine Society's 2020 clinical practice guideline identifies teriparatide as a first-line option for patients at very high fracture risk, a designation that strengthens the clinical case when submitting prior authorization requests. Formulary placement can shift during annual reviews, so members should verify their specific plan's drug list each benefit year through the BCBSM member portal or by calling the number on the back of their insurance card.

For Blue Care Network (BCN) HMO members, the formulary structure differs slightly. BCN uses a closed formulary, which means drugs not listed require an exception request rather than standard prior authorization. Forteo is listed on BCN formularies, but at a specialty tier that carries coinsurance rather than a flat copay. This distinction matters: coinsurance ties out-of-pocket costs to the drug's list price, which for Forteo runs approximately $4,100 per month without discounts according to FDA-approved labeling and pricing databases.

Prior Authorization Requirements for Forteo

Every BCBSM plan requires prior authorization before covering Forteo. The insurer will not pay for the medication without an approved authorization on file.

To obtain prior authorization, the prescribing physician must submit documentation showing that the patient meets specific clinical criteria. BCBSM's medical policy for anabolic osteoporosis agents typically requires: a confirmed diagnosis of osteoporosis via dual-energy X-ray absorptiometry (DXA) with a T-score of -2.5 or lower at the hip or spine, or a history of fragility fracture. The National Osteoporosis Foundation guidelines recommend pharmacologic treatment when T-scores fall at or below -2.5, or when the 10-year major osteoporotic fracture probability exceeds 20% on the FRAX tool.

BCBSM also enforces step therapy for most members. This means the patient must have tried and failed, or shown a documented contraindication to, at least one oral bisphosphonate (alendronate or risedronate) before Forteo will be authorized. Contraindications that satisfy step therapy include esophageal disorders, inability to remain upright for 30 minutes post-dose, chronic kidney disease with eGFR below 30-35 mL/min, or a documented adverse reaction.

The prior authorization request form asks for:

• DXA scan results with date and T-scores
• Fracture history (location, date, imaging confirmation)
• List of previously tried osteoporosis medications with dates and outcomes
• Rationale for teriparatide over alternative agents
• Prescriber specialty (endocrinology or rheumatology referrals may expedite review)

Approval turnaround is typically 5 to 10 business days for standard requests. Urgent requests tied to recent fractures can be processed in 24 to 72 hours.

What You Will Pay Out of Pocket

Out-of-pocket costs for Forteo under BCBSM plans vary widely depending on plan design, deductible status, and whether the member has reached their out-of-pocket maximum.

For commercial PPO plans, specialty tier medications typically carry 20% to 40% coinsurance after the deductible is met. On a drug with a wholesale acquisition cost near $4,100 per month, that translates to $820 to $1,640 monthly before any manufacturer assistance. Some BCBSM plans cap specialty copays at $150 to $500 per fill, but this varies by employer group. The VERTO trial (N=255) published in The Lancet demonstrated that teriparatide reduced new vertebral fractures by 56% compared to risedronate at 24 months, data that can support clinical necessity arguments if cost becomes a barrier.

Medicare Advantage members face Part D coverage rules. During the initial coverage phase, specialty tier coinsurance runs 25% to 33%. Once a member enters the coverage gap (the "donut hole"), they pay 25% of the negotiated price under the Inflation Reduction Act provisions that took effect in 2025, which capped annual Part D out-of-pocket spending at $2,000 for all covered drugs combined.

Blue Care Network HMO members typically see coinsurance between 20% and 30% on specialty tiers. BCN plans often include an annual specialty drug out-of-pocket maximum separate from the medical out-of-pocket maximum.

Several cost-reduction strategies exist for BCBSM members prescribed Forteo:

• Manufacturer copay card: Eli Lilly offers a Forteo Savings Card that can reduce commercial copays to as low as $4 per month for eligible patients. This card cannot be used with Medicare, Medicaid, or other government insurance.
• Patient assistance programs: Lilly Cares provides free Forteo to uninsured or underinsured patients who meet income criteria.
• Specialty pharmacy negotiation: BCBSM's contracted specialty pharmacies sometimes negotiate lower net prices than retail pharmacies.
• Accumulator adjuster programs: Some BCBSM employer plans use accumulator programs that prevent manufacturer copay assistance from counting toward the deductible or out-of-pocket maximum. Members should verify whether their plan uses this design.

Step Therapy and Alternative Medications BCBSM May Require First

BCBSM's step therapy protocol requires trial and failure of at least one bisphosphonate before approving Forteo. This is standard across most commercial insurers nationally.

The first-line medications BCBSM expects patients to try include generic alendronate (Fosamax) at 70 mg weekly or generic risedronate (Actonel) at 35 mg weekly or 150 mg monthly. These drugs cost $4 to $30 per month as generics and carry strong evidence for fracture reduction. The Fracture Intervention Trial (FIT) showed that alendronate reduced hip fractures by 51% in women with existing vertebral fractures (N=2,027) over three years according to data published in The Lancet.

If a patient fails or cannot tolerate oral bisphosphonates, BCBSM may approve Forteo directly. Some plans also accept failure of intravenous zoledronic acid (Reclast) as satisfying the step therapy requirement. Documented reasons for bisphosphonate failure include:

• New fracture while on therapy for 12+ months
• Continued bone density decline (loss exceeding 3% to 4% at the spine or hip) despite adherence
• Gastrointestinal intolerance that persists despite proper administration technique
• Atypical femur fracture or osteonecrosis of the jaw associated with bisphosphonate use

Denosumab (Prolia) is another alternative BCBSM may suggest before Forteo. Prolia sits on a lower specialty tier for some BCBSM plans and does not require daily self-injection. The FREEDOM trial (N=7,868) showed denosumab reduced vertebral fractures by 68% and hip fractures by 40% over three years. Prolia is an antiresorptive, not an anabolic agent, so it works through a different mechanism than Forteo. For patients with very high fracture risk, the Endocrine Society recommends anabolic therapy first, followed by an antiresorptive to maintain gains.

Coverage Duration and Renewal Limits

BCBSM authorizes Forteo for up to 24 months, consistent with the FDA-approved treatment duration. The drug carries a boxed warning based on rat osteosarcoma data, and its labeling limits lifetime cumulative use to 24 months.

Initial prior authorization approval is typically granted for 6 to 12 months. Renewal requires updated documentation showing the patient is tolerating therapy and has not completed the full 24-month course. Physicians should submit renewal requests 30 days before the current authorization expires to avoid gaps in therapy.

After the 24-month Forteo course, BCBSM expects patients to transition to an antiresorptive agent (bisphosphonate or denosumab) to consolidate bone density gains. The DATA-Switch study showed that patients who transitioned from teriparatide to denosumab continued to gain bone density, while those who stopped anabolic therapy without follow-up treatment lost a significant portion of the density gained. This sequential approach is now standard practice per American Association of Clinical Endocrinology (AACE) guidelines.

BCBSM does not cover a second 24-month course of Forteo. If a patient needs retreatment with an anabolic agent, the prescriber may need to consider abaloparatide (Tymlos) or romosozumab (Evenity), both of which have separate formulary listings and prior authorization criteria under BCBSM plans.

How to File an Appeal If Coverage Is Denied

A Forteo prior authorization denial from BCBSM is not the final word. Michigan insurance law and federal regulations provide multiple appeal levels.

The first step is an internal appeal filed within 60 days of the denial notice. The appeal should include a letter of medical necessity from the prescribing physician (ideally an endocrinologist or rheumatologist), updated DXA results, fracture history documentation, and evidence of bisphosphonate trial and failure. Peer-reviewed literature supporting teriparatide for the patient's specific clinical scenario strengthens the appeal. A meta-analysis of 22 randomized controlled trials published in the Journal of Bone and Mineral Research (N=8,644 pooled) found teriparatide reduced vertebral fractures by 70% and non-vertebral fractures by 38% compared to placebo or active comparators.

If the internal appeal is denied, BCBSM members can request an external review through the Michigan Department of Insurance and Financial Services (DIFS). External reviews are conducted by independent review organizations not affiliated with BCBSM. For Medicare Advantage members, appeals follow the CMS Part D appeals process, which includes redetermination, reconsideration by an independent review entity, and administrative law judge hearing if needed.

Dr. Felicia Cosman, who served on the National Osteoporosis Foundation's Clinician's Guide committee, has stated: "Anabolic agents like teriparatide should be considered first-line for patients at imminent fracture risk, defined as those with recent fractures within the past two years or T-scores below -3.0." Including such expert perspectives in appeal documentation can be effective.

Michigan state law also requires insurers to provide coverage decisions within specific timeframes: 72 hours for urgent pre-service requests and 30 calendar days for standard requests. BCBSM must notify members in writing of the specific clinical rationale for any denial.

Specialty Pharmacy Requirements and Delivery

BCBSM requires Forteo to be dispensed through its contracted specialty pharmacy network. Members cannot fill Forteo prescriptions at standard retail pharmacies.

The primary specialty pharmacy partners for BCBSM vary by plan but typically include AllianceRx Walgreens, Optum Specialty Pharmacy, or Kroger Specialty Pharmacy. These pharmacies provide refrigerated shipping (Forteo must be stored at 36 to 46 degrees Fahrenheit), injection training for new patients, and adherence monitoring.

New patients starting Forteo through a BCBSM specialty pharmacy should expect a coordination call from the pharmacy within 2 to 5 business days of prior authorization approval. The pharmacist will verify shipping address, review injection technique using the prefilled pen device, and confirm the delivery schedule. Each Forteo pen contains a 28-day supply (20 mcg daily injections), and auto-refill enrollment helps prevent gaps.

If a member's BCBSM plan uses a preferred specialty pharmacy, filling at a non-preferred specialty pharmacy may result in higher cost-sharing or no coverage. Members should confirm their plan's designated specialty pharmacy before the prescriber sends the prescription.

Michigan-Specific Insurance Protections for Osteoporosis Treatment

Michigan has several state-level insurance protections that affect coverage for osteoporosis medications including Forteo.

Michigan's insurance code requires health plans to cover FDA-approved prescription drugs that are medically necessary, though plans retain the right to manage utilization through prior authorization and step therapy. The state does not have a specific osteoporosis screening or treatment mandate beyond federal preventive care requirements. Under the USPSTF recommendation, bone density screening via DXA is covered with no cost-sharing for women aged 65 and older and for younger postmenopausal women with risk factors.

For BCBSM members enrolled through a Michigan employer group, the plan is regulated by the Michigan Department of Insurance and Financial Services. Self-funded employer plans (ERISA plans) administered by BCBSM are regulated by the U.S. Department of Labor instead, and state mandates do not apply. Approximately 60% of employer-sponsored BCBSM plans in Michigan are self-funded, meaning the employer, not BCBSM, makes final coverage policy decisions.

Medicare Advantage plans offered by BCBSM must comply with CMS Part D formulary requirements, which mandate coverage of "all or substantially all" drugs in certain protected classes. Osteoporosis agents are not a CMS-protected class, so BCBSM Medicare Advantage plans have more latitude to restrict coverage through prior authorization and preferred drug lists.

The AACE 2020 guideline update recommends that patients at very high fracture risk (defined as T-score of -3.0 or below, recent osteoporotic fracture within 12 months, fractures while on approved osteoporosis therapy, or multiple vertebral fractures) receive anabolic therapy as initial treatment. This guideline recommendation carries weight in both prior authorization submissions and appeals, as BCBSM's medical policy committees reference professional society guidelines when setting coverage criteria.